Full interpretation of the launch date, indications and domestic sales of voclosporin soft capsules

Voclosporin (Voclosporin) is a new oral calcineurin inhibitor (CNI) developed by Aurinia Developed by Pharmaceuticals, it is mainly used to treat systemic lupus erythematosus (SLE) accompanied by active lupus nephritis (lupus nephritis). Its mechanism of action is similar to that of cyclosporine, but after structural optimization, it has more stable pharmacokinetic properties and more controllable immunosuppressive effects, which can effectively reduce glomerular inflammatory response and improve proteinuria and renal function.

The original drug of cyclosporin has been on the market overseas for many years and is mainly used for the adjuvant treatment of lupus nephritis. Clinical studies have shown that combining standard immunosuppressive treatments (such as glucocorticoids and mycophenolate mofetil) can significantly increase the rate of improvement in renal function and reduce proteinuria levels. Its long-term efficacy and safety data also show that while controlling disease activity, cyclosporin has a relatively controllable impact on liver and kidney function. The main adverse reactions are mild to moderate hypertension and mild gastrointestinal reactions.

In the domestic market, the original drug of cyclosporin has not yet been launched on the market, so patients cannot purchase it directly through formal domestic channels, and the medical insurance reimbursement policy has not yet been established. The overseas European version of the original drug has a specification of 7.9mg Currently, there are no generic drugs on the market in China. If patients need medication, they need to obtain it through regular overseas channels and use it under the guidance of a doctor.

Overall, cyclosporine, as a new immunosuppressive drug for lupus nephritis, has the characteristics of precise efficacy, stable pharmacodynamics and controllable side effects. Although it has not yet been marketed in China, it has rich clinical application experience overseas and can provide new treatment options for patients with severe lupus nephritis. In the future, with the domestic launch and the establishment of medical insurance policies, it is expected to bring more accessible treatment opportunities to patients.

Reference materials:https://www.drugs.com/